China
Africa
Explore chapters and articles related to this topic
Congenital cardiac anomalies
Published in Brice Antao, S Irish Michael, Anthony Lander, S Rothenberg MD Steven, Succeeding in Paediatric Surgery Examinations, 2017
Protein-losing enteropathy is a recognised long-term complication of single ventricle patients who have been palliated with the Fontan procedure, whereby systemic venous blood passively drains into the pulmonary arteries, while pulmonary venous return is actively pumped by the systemic single ventricular mass into the systemic circulation. The aetiology of protein-losing enteropathy is unclear and the mortality is high, approaching 50% by 1 year following diagnosis. Various treatment modalities have been tried, all with little long-term success. Definitive treatment is heart transplantation.
Functionally single ventricle, Fontan procedure – univentricular heart/circulation
Published in Jana Popelová, Erwin Oechslin, Harald Kaemmerer, Martin G St John Sutton, Pavel Žáček, Congenital Heart Disease in Adults, 2008
Jana Popelová, Erwin Oechslin, Harald Kaemmerer, Martin G St John Sutton, Pavel Žáček
Development of protein-losing enteropathy following Fontan operation implies a very grim prognosis. This complication occurs in 3.7–25% of patients undergoing Fontan operation, most often at 4 years postoperatively; still, it may occur even later. The incidence of protein-losing enteropathy also depends on the eligibility of patients scheduled for Fontan operation; the figure was a mere 1.3% in the series of Pediatric Heart Center of the Prague Motol University Hospital.20 In an international multicenter study including more than 3000 patients after Fontan operation, protein-losing enteropathy was found in 3.7% of the survivors. The survival of patients developing protein-losing enteropathy was 59% at 5 years and <20% at 10 years.21
Novel PLVAP Mutation in Protein Losing Enteropathy
Published in Fetal and Pediatric Pathology, 2019
Orhan Gorukmez, Ozlem Gorukmez, Kaan Demiroren
The conditions of protein-losing enteropathy (PLE) caused by genetic disorders are usually congenital in onset and clinically serious [1]. Diarrhea 10 (DIAR10, MIM 618183) is a type of PLE associated with the plasmalemma vesicle protein (PLVAP) gene. DIAR10 abnormalities accompanied by intestinal and extraintestinal findings have been reported in a small number of patients. Therefore, the pathogenesis of the disease is not clear, and the mechanism of the disease will be better understood as the number of cases increases [1–3]. For this purpose, a female patient with DIAR10 is presented in detail with her clinical and genetic aspects.
A novel nonsense variation in the albumin gene (c.1309 A>T) causing analbuminaemia
Published in British Journal of Biomedical Science, 2021
G Caridi, A Farokhnia, F Lugani, AM de Luca, M Campagnoli, M Galliano, D Schröpfer, L Minchiotti
Other investigations were negative: hepatitis A/B/C,HIV, stool pancreatic elastase, a serologic panel screening against multiple intestinal parasites, and haemoglobinopathies (with normal HbF and HbA2). The activities of the erythrocyte enzymes glucose-6-phosphate dehydrogenase and pyruvate kinase were also normal. Gastroenterologists, using ultrasound of the abdomen and extensive specialist investigations, could not ascertain the cause of the low albumin level. A protein-losing enteropathy was excluded since the patient was asymptomatic. It was therefore also considered unnecessary to screen for an inflammatory bowel disease.
Abdominal lymphadenopathy in children with Gaucher disease: Relation to disease severity and glucosylsphingosine
Published in Pediatric Hematology and Oncology, 2022
Azza Abdel Gawad Tantawy, Amira Abdel Moneam Adly, Heba Mohamed Atif, Sherihane Said Madkour, Nouran Yousef Salah
ALN has been reported to be rare in children with GD with few case reports and series reported worldwide.5–12 Its development has been described with varying clinical manifestations, including intestinal obstruction and protein losing enteropathy. In most cases, it was described in patients on enzyme replacement therapy (ERT) with no role for the ERT in reversing the pathology.7,9,12 However, its prevalence among Gaucher population, pathophysiology, clinical implications and laboratory determinants are unknown, with no consensus on treatment strategies.